A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205

Trial Profile

A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs ASP 2205 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Jun 2016 Status changed from suspended to discontinued because of operational reasons.
    • 12 Aug 2015 Planned End Date changed from 1 Aug 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
    • 12 Aug 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top